Dr. Arlene Chapman is a distinguished nephrologist and Professor of Medicine at the University of Chicago, where she also serves as the Chief of the Section of Nephrology. She is a member of the American Association of Physicians and the American Clinical and Climactologic Association. Her clinical efforts and research focuses on hereditary kidney diseases, particularly autosomal dominant polycystic kidney disease (ADPKD), essential hypertension, and the intersection of kidney function and pregnancy.
Over the past three decades, Dr. Chapman has been a leading figure in ADPKD research, contributing to the development of magnetic resonance imaging techniques to assess total kidney volume (TKV), a key biomarker in disease progression. Her work has been instrumental in advancing clinical trials for novel therapies, including vasopressin V2 receptor antagonists and rigorous blood pressure control strategies.
In recognition of her significant contributions, Dr. Chapman received the 2020 Lillian Jean Kaplan International Prize from the International Society of Nephrology. This award honors her pioneering efforts in ADPKD research, the development of Vasopressin V2 receptor antagonists. the development of TKV as a prognostic imaging biomarker and her leadership in interventional clinical trials that have led to FDA-approved treatments for ADPKD.
Beyond her research, Dr. Chapman is a dedicated educator and mentor, actively involved in training medical students, residents, fellows and faculty. She has published over 200 peer-reviewed articles and 20 book chapters and has served on the editorial boards of several prominent nephrology journals.
Dr. Chapman is an Associate Director of the Institute for Translational Medicine and Director of the Clinical Research Center at the University of Chicago and has recently established a whole room calorimetry core for investigators interested in energy expenditure and metabolism. Dr. Chapman continues to lead innovative research initiatives across different medical disorders and plays a key role in clinical research leadership at the University of Chicago.
Prognostic Performance of Ellipsoid Kidney Volume Measurement in a Computed Tomography-Heavy ADPKD Cohort: A Retrospective Observational Cohort Study.
Prognostic Performance of Ellipsoid Kidney Volume Measurement in a Computed Tomography-Heavy ADPKD Cohort: A Retrospective Observational Cohort Study. Can J Kidney Health Dis. 2026; 13:20543581261479801.
PMID: 42605313
Peritoneal Dialysis Outcomes in Autosomal Dominant Polycystic Kidney Disease.
Peritoneal Dialysis Outcomes in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2026 Jul 31.
PMID: 42536420
A pilot study of magnetic resonance fingerprinting and radiomics analysis in autosomal dominant polycystic kidney disease.
A pilot study of magnetic resonance fingerprinting and radiomics analysis in autosomal dominant polycystic kidney disease. Kidney Int. 2026 Jun 16.
PMID: 42302929
Future needs for clinical trials in autosomal dominant polycystic kidney disease.
Future needs for clinical trials in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2026 Jun; 22(6):379-380.
PMID: 41876870
Pregnancy and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
Pregnancy and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2026 May 18.
PMID: 42149684
Renal blood flow and progression to kidney failure in ADPKD.
Renal blood flow and progression to kidney failure in ADPKD. Nephrol Dial Transplant. 2026 Mar 11.
PMID: 41811969
Relationship between Total Kidney Volume and eGFR in Autosomal Dominant Polycystic Kidney Disease.
Relationship between Total Kidney Volume and eGFR in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2026 Feb 13.
PMID: 41686506
Development and Validation of a Multivariable Prediction Model for Kidney Failure in Early Autosomal Dominant Polycystic Kidney Disease.
Development and Validation of a Multivariable Prediction Model for Kidney Failure in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2026 May 01; 37(5):1010-1021.
PMID: 41563252
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy.
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy. Clin Pharmacol Ther. 2025 12; 118(6):1430-1436.
PMID: 40974042
ADPKD Progression by Variant Type and Molecular Domain Among Participants in the HALT PKD Trial.
ADPKD Progression by Variant Type and Molecular Domain Among Participants in the HALT PKD Trial. Clin J Am Soc Nephrol. 2025 Nov 01; 20(11):1516-1526.
PMID: 40762980